pharma · Autoimmune Epilepsy · OPTN
Option Therapeutics
Option Therapeutics patent portfolio — 10 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- CARSON CITY, NV, USA
- Founded
- 2023
- Employees
- 2
- Programs
- 1
- Drugs
- 1
- Patents
- 10
Option Therapeutics patents
10 pharmaceutical patents indexed for Option Therapeutics. 0 expire within 24 months.
Option Therapeutics has 10 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 11596610
Compositions in support of health and mental accuity
granted -
US 10117937
Highly branched alpha-D-glucans
granted -
US 9289513
Targeted cytokine for treatment of musculoskeletal diseases
granted -
US 8685932
Targeted transforming growth factor-beta-bound IgG for Treatment of Diseases
granted -
US 6770283
DNA expression systems based on alphaviruses
expired -
US 6692750
Alphavirus expression vector
expired -
US 6566093
Alphavirus cDNA vectors
expired -
US 6224879
Alphavirus expression vector
expired -
US 6190666
DNA expression systems based on alphaviruses
expired -
US 6013122
Tattoo inks
expired
Frequently asked questions
How many patents does Option Therapeutics have?
10 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Option Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.